Weifa ASA, through its subsidiary, Weifa AS, manufactures and sells non-prescription, over-the-counter pharmaceutical products in Norway, Denmark, Iceland, Sweden, and Finland. Its primary products include Paracet and Paracetduo for mild to moderate pains, such as headaches, muscle and joint pains, discomfort related to fever, influenza and colds, and menstrual pain and toothache; and Ibux, an ibuprofen product for menstrual pain, headache, inflammation, and pains in muscles and joints. The company also provides Pyrisept for wound disinfection; Paralgin forte for moderate pain; Bronkyl and Bronkyl forte for chesty cough; Dexyl nasal decongestion sprays; Trampalgin pain killers; Ibux gel, an anti-inflammatory cooling gel for local pain treatment; Complete Multi, a range of dietary supplements; Pyricare, a sterile saltwater spray; Zonat (Rx) for insomnia; and Solvivo for mild mouth and throat infections. In addition, it develops drugs comprising CP-4200, a LVT derivative of azacytidine, which acts as a modifier of gene expression that is approved in the United States of America; and CP-4033, a ribavirin elaidate, the LVT derivative of ribavirin that is in pre-clinical development stage for aggressive thyroid cancer. The company was formerly known as Aqualis ASA and changed its name to Weifa ASA in August 2014. Weifa ASA was founded in 1940 and is headquartered in Oslo, Norway. As of October 6, 2017, Weifa ASA operates as a subsidiary of Karo Pharma AB (publ).